ABSTRACT
Although Candida albicans is the most common isolate from human infections, other Candida species have also been observed in the 1990s, supporting the increased frequency of non-albicans species (1) (2) . Candida parapsilosis is a common yeast species found in cases of onychomycosis and candidemia associated with infected intravascular devices (3) (4) (5) (6) . In State of Goiás, Brazil, C. parapsilosis was found in 52.5% of nail samples and was the second most commonly isolated species (24.2%) from blood cultures (4) (7) . Previous work has shown that C. parapsilosis isolates may exhibit genotypic differences, allowing the classification of new species by restriction polymorphism analysis of the secondary alcohol dehydrogenase (SADH) gene.
Candida parapsilosis forms a complex composed of three genetically distinct species: C. parapsilosis sensu stricto, Candida orthopsilosis, and Candida metapsilosis (8) . C. parapsilosis complex species are usually susceptible to antifungal agents; however, some reports have shown that these isolates may exhibit decreased susceptibility to azoles and echinocandins (9) . This difference in antifungal susceptibility among the three species has led to an increased interest in the study of C. parapsilosis complex species (10) . Moreover, antifungal susceptibility surveillance is an important major strategy for the prophylaxis and treatment of candidiasis caused by C. parapsilosis.
Because of the medical importance of C. parapsilosis in our area and the limited local epidemiological data on this species, we aimed to verify the distribution of C. parapsilosis sensu stricto, C. orthopsilosis, and C. metapsilosis species within a culture collection containing blood and subungual scraping samples from patients attending a tertiary hospital
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in Goiás, Brazil. Additionally, we assessed the in vitro antifungal susceptibility of these species to fl uconazole (FLC), itraconazole (ITC), voriconazole (VOR), posaconazole (POS), amphotericin B (AMB), and caspofungin (CAS).
Isolates
A total of 87 C. parapsilosis isolates were recovered from different clinical specimens, including blood (737) and nail specimens (136). These isolates were stored at -70°C in yeast extract peptone dextrose (YEPD) broth (Difco) with 10% glycerol and were obtained from the Laboratory of Mycology, Institute of Tropical Pathology and Public Health, Federal University of Goiás from 2007 to 2012.
Candida parapsilosis was obtained from adult patients with candidemia (n = 54) and onychomycosis (n = 33). The study was approved by the Bioethic Committee from Hospital das Clínicas in Goiânia-GO (protocol 065/2008). Confirmation of the identifi cation of C. parapsilosis sensu lato, after subculture on YEPD agar (Difco) for 48h at 37°C, was based on colony color on CHROMagar Candida medium (Difco), micromorphology of colonies on cornmeal agar medium (Difco), and assimilation profi les on ID32C (BioMérieux, France). C. parapsilosis ATCC 22019 was included as quality control strain.
Molecular identifi cation of the Candida parapsilosis complex species
Genomic deoxyribonucleic acid (DNA) was extracted from each isolate using high-speed cell disruption followed by phenol-chloroform extraction and ethanol precipitation, as described by Tavanti et al. (8) .
Polymerase chain reaction (PCR) was carried out to amplify the SADH gene using the primers S1F (5′-GTTGATGCTGTTGGATTGT-3′) and SIR (5′-CAATGCCAAATCTCCCAA-3′) and conditions previously described by Tavanti et al. (8) Amplifi cation was performed in a T100 thermal cycler (Bio-Rad, Hercules, CA, USA), and the amplifi ed products were loaded onto 2% agarose gels containing ethidium bromide (0.5mg/mL). A 100-bp DNA ladder was used as a molecular size marker (Invitrogen Life Technologies, USA). Amplifi ed products were electrophoresed on 1.5% agarose gels, visualized under ultraviolet light, and analyzed on a photo documenter (Bio-Rad).
The PCR products (fragments of 716bp) were purifi ed with a specialized kit (Qiagen, Valencia, CA, USA), and digestion of the purifi ed PCR product was carried out for 120 min at 37°C using the restriction enzyme BanI (Thermo Scientifi c, USA). Digestion of the PCR products was subjected to electrophoresis onto 2% agarose gels (Invitrogen Life Technologies). C. parapsilosis ATCC 22019, C. orthopsilosis ATCC 96141, and C. metapsilosis ATCC 96143 were used as controls.
In vitro susceptibility testing
All isolates were evaluated using Etests (AB Biodisk, Solna, Sweden), as recommended by the manufacturer's guidelines, with Etest strips for ITC, VOR, POS, AMB, and CAS at concentrations ranging from 0.002 to 32µg/mL and for FLC at concentrations ranging from 0.016 to 256µg/mL. C. parapsilosis ATCC 22019 was included on each day of testing to verify the reproducibility of the results.
Interpretative criteria for FLC minimum inhibitory concentrations (MICs) were as follows: ≤ 2µg/mL, susceptible; 4µg/mL, susceptible-dose dependent (S-DD), and ≥8µg/mL, resistant. ITC and VOR MICs were interpreted as follows: ≤0.125µg/mL, susceptible; 0.25-0.5µg/mL, S-DD; and ≥ 1µg/mL, resistant. Caspofungin MICs were interpreted as follows: ≤2µg/mL, susceptible; 4µg/mL, intermediate; and ≥8µg/mL, resistant (11) (12) . Isolates with MICs of greater than 1µg/mL were considered resistant to AMB and POS, as suggested by Nguyen et al. (13) and Cantón et al. (3) .
Among the 87 isolates, 78 (89.7%) were identified as C. parapsilosis sensu stricto (two restriction sites), fi ve (5.7%) were identifi ed as C. orthopsilosis (no restriction sites), and four (4.6%) were identifi ed as C. metapsilosis (four restriction sites). In blood samples, 47 (54.1%), fi ve (5.7%), and two (2.3%) isolates were C. parapsilosis, C. metapsilosis, and C. orthopsilosis, respectively. In nail samples, C. parapsilosis and C. metapsilosis represented 31 (35.6%) and two (2.3%) isolates, respectively. BanI restriction profiles of SADH fragments used for distinguishing among the three species of the C. parapsilosis complex are shown in Figure 1 .
According to the interpretative criteria for resistance used for the antifungal drugs described in the Material and Methods, we found that very few isolates were resistant to azoles and AMB. One C. parapsilosis sensu stricto isolate was resistant to AMB and ITC. Moreover, 10.2% of C. parapsilosis sensu stricto isolates weare resistant to CAS. Two C. parapsilosis sensu stricto isolates and one C. metapsilosis isolate met the criterion for S-DD to FLC.
Susceptible-dose dependent strains were detected in the three species. C. orthopsilosis met the criterion for S-DD to ITC; C. metapsilosis and C. parapsilosis sensu stricto met the criterion for S-DD to ITC and FLC; and isolates of all three species exhibited intermediate susceptibility to CAS. The profi les of the in vitro susceptibility of C. parapsilosis complex species to azoles, AMB, and CAS, including MIC ranges, MIC 50 , MIC 90 , susceptibility intermediate or S-DD, and resistance, are summarized in Table 1 .
Within the genus Candida, C. parapsilosis is the second most commonly isolated species from blood cultures in several casuistics (5) (14) (15) . Moreover, this species represents frequent cause of onychomycosis in several countries, including Brazil (4) , Chile (16) , México (17) , and Iran (18) . Although all 87 isolates of C. parapsilosis studied in our work have been identifi ed by phenotypic methods, we were not able to differentiate among the C. parapsilosis complex species, which are phenotypically identical. Amplifi cation of the SADH gene followed by BanI restriction enzyme digestion has been used as a rapid and reliable method with high discriminative power for C. parapsilosis complex species (6) (19) (20) (21) . Data have shown that these three species exhibit different prevalence rates, virulence, and in vitro antifungal susceptibility (3) (10) (19) (22) (23) (24) . In vitro studies have also shown that C. parapsilosis sensu stricto is more pathogenic than C. orthopsilosis, which is, in turn, is more pathogenic than C. metapsilosis (25) .
In our study, C. parapsilosis sensu stricto was the dominant species among blood isolates, followed by C. orthopsilosis and C. metapsilosis. Similar to our results, some researchers have shown that C. parapsilosis sensu stricto is the most frequently found species in patients with candidemia (3) (15) (26) (27) . The high frequency of this species in blood samples in critically ill patients may be explained by several factors, including the high affi nity of these species for vascular devices and medical instrumentation and their capacity for colonization on the hands of healthcare workers (28) (29) . Several studies have found variations in the frequencies of C. orthopsilosis and C. metapsilosis in candidemia cases. In Spain, among the 171 strains identifi ed as part of the C. parapsilosis complex, 2.4% were shown to be C. orthopsilosis, and 1.2% were shown to be C. metapsilosis (30) . In Brazil, a study by Ruiz et al. (31) showed frequencies of 10.2% for C. orthopsilosis and 6.1% for C. metapsilosis in strains isolated from blood. Moreover, some studies have shown that C. metapsilosis does not cause bloodstream infections (32) (33) . A possible explanation for low frequency or absence of C. metapsilosis as the cause of candidemia is its poor ability to express virulence factors (34) . Similar to samples obtained from blood, we observed a predominance of C. parapsilosis sensu stricto among isolates from nail samples, followed by C. metapsilosis. However, C. orthopsilosis was not found. Mohammadi et al. (35) have shown that C. parapsilosis sensu stricto is the dominant species, followed by C. orthopsilosis. In contrast, similar to our results, Ge et al. (19) have found that C. parapsilosis sensu stricto and C. metapsilosis are the agents responsible for onychomycosis. Among C. parapsilosis complex species, the two species newly identifi ed as C. orthopsilosis and C. metapsilosis have been less frequently isolated from patients with onychomycosis (6) (36) .
Antifungal resistance or tolerance of C. parapsilosis complex species is a growing concern in the context of current and new antifungal agents; this has been a major topic of discussion and concern among infectious disease physicians. According to some researchers, C. parapsilosis sensu stricto isolates are less susceptible to some antifungals used for the treatment of candidiasis, such as AMB, FLC, ITC, and CAS, when compared with the susceptibility of C. orthopsilosis and C. metapsilosis isolates (9) (31) (37) (38) . Among the azole derivatives analyzed in our study, ITC was less active. Consistent with this, Ruiz et al. (31) found resistance in one C. parapsilosis sensu stricto isolate and S-DD in 100% of C. orthopsilosis isolates and 66.6% of C. metapsilosis isolates in response to ITC. Figueiredo-Carvalho et al. (39) verifi ed that C. orthopsilosis isolates are less susceptible to ITC than the other species in the C. parapsilosis complex.
In this study, C. parapsilosis complex isolates were not resistant to FLC; however, S-DD criteria were met for two C. parapsilosis sensu stricto isolates and one C. metapsilosis isolate. Similarly, FLC resistance in C. metapsilosis and C. parapsilosis sensu stricto has been observed by Chen et al. (40) Moreover, Gomez-Lopez et al. (41) found an MIC of greater than 4µg/mL FLC for these species, while Silva et al. (6) found an MIC of 16µg/mL FLC for one C. parapsilosis sensu stricto isolate. According to Van Asbeck et al. (42) , the differences in FLC susceptibility may also refl ect the different affi nities of azoles for the key ergosterol-synthesizing enzyme 14-α-demethylase or for other enzymes in this pathway.
Interestingly, all isolates of the C. parapsilosis complex were susceptible to the new triazole antifungal agents tested in this study (i.e., VOR and POS). These results are consistent with several studies demonstrating the greater effi cacy of these new triazoles against C. parapsilosis complex isolates (6) (9) (39) (41) (43) .
In this study, we considered an isolate resistant to AMB when the MIC was greater than 1µg/mL. Thus, in our study, only one C. parapsilosis sensu stricto isolate was classifi ed in this category. Although Lockhart et al. (26) reported MICs of more than 1µg/mL for these three species, they found that the proportion of AMB-resistant C. parapsilosis sensu stricto is higher than those of C. orthopsilosis and C. metapsilosis.
Although Trabasso et al. (44) observed some fluctuations in MIC values between the three C. parapsilosis complex species, they also showed that these isolates were susceptible to echinocandin, with MIC values within those of the reference strain or the proposed MIC values (CLSI). However, 19.5% (17/87) of C. parapsilosis complex isolates studied in our work were less susceptible to CAS, with resistance detected in eight isolates of C. parapsilosis sensu stricto (Table 1) . Several studies have shown that the MIC of CAS in C. parapsilosis sensu stricto is higher than that of the two species within the complex (26) (40) (41) . However, the reason for the high MIC values for CAS is unclear (45) . Recent works have described a functional point mutation in the glucan synthase (FKS) gene of the C. parapsilosis complex species, which may explain this observation (46) (47) . FKS gene mutations have been shown to be associated with resistance to CAS, as demonstrated by increases in MICs in mutant isolates compared with those of wild-type isolates (48) (49) (50) . In summary, our study reported the first molecular identifi cation of C. parapsilosis complex species in State of Goiás, Brazil. We provided evidence showing that although C. parapsilosis sensu stricto was the dominant species among the three C. parapsilosis complex species, the other two species (C. metapsilosis and C. orthopsilosis) have clinical importance as pathogens in candidemia and onychomycosis. Moreover, we observed important differences in antifungal susceptibility profi les among the three species, mainly with regard to CAS.
